Affiliation:
1. State Key Laboratory of Bioactive Substance and Function of Natural Medicines and Beijing Key Laboratory of Active Substances Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
Abstract
Background:
For decades, a great deal of research work has been done to synthesize ellipticine and
its derivatives because of their potential antitumor properties and anti-HIV activities. However, the resonance
structures in different media, a low level of solubility at physiological pH and systemic toxicity have prevented
the use of ellipticine as a therapeutic agent. Besides, the low yield and complex steps of ellipticine synthesis limit
its application.
Methods:
A high-yield synthetic procedure of ellipticine has been optimized, and the total yield was up to 50%
without silica gel column chromatography. Novel hexacyclic ellipticine derivatives were synthesized by coupling
ellipticine with o-aminobenzoic acid. Their cytotoxicities against HCT116, MGC803, HT29 and MCF-7 tumor
cells were evaluated.
Results:
The synthesis process of ellipticine was optimized, and the total yield of the synthetic route was increased
to 50% through several operation steps optimization. Fourteen ellipticine hexacyclic derivatives were
synthesized. The synthetic compounds were screened for anti-tumor activity in vivo and in vitro, and some of the
derivatives had good anti-tumor activity.
Conclusion:
Compared with ellipticine, the compound 1l showed higher antitumor activity and better tolerance to
tumor models. The compound 1l treatment increased the percentage of late apoptotic cells from 3.1% (DMSO) to
21.6% (20.0 μM) in NCI-H460 cells. It also was observed the effect of 1l on G2 phase arrest was similar as that
of ellipticine. The mechanism of action indicated compound 1l could be a topoisomerase IIα poison. These studies
provided the basis for the pharmacodynamics and toxicology of ellipticine, and further clarifies the structureactivity
relationship of antitumor activity of ellipticine.
Funder
Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
Open Fund of State Key Laboratory of Bioactive Substance and Function of Natural Medicines
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献